{
    "nctId": "NCT04131231",
    "briefTitle": "Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion",
    "officialTitle": "Safety and Effectiveness of Microparticles Packaging Chemotherapeutic Drugs(MPCD) Therapy on the Treatment of Malignant Pleural Effusion",
    "overallStatus": "UNKNOWN",
    "conditions": "Lung Cancer, Breast Cancer, Malignant Pleural Effusion",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 248,
    "primaryOutcomeMeasure": "Objective Response Rate\uff08ORR\uff09",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histologically confirmed as lung cancer or breast cancer;\n2. Cytologically or histologically confirmed MPE needing thoracocentesis treatment;\n3. Without thoracocentesis treatment within 4 weeks;\n4. ECOG PS score: 0-2 points;\n5. Predicted life expectancy greater than 3 months;\n6. 18 years \u2264Age \u226480 years\uff1b\n7. Bone marrow function: hemoglobin(HGB) \u226590g/L\uff0cwhite blood cells(WBC) \u22653.0\u00d710\\^9/L\uff0cabsolute neutrophil count(ANC) \u22651.5\u00d710\\^9/L\uff0cplatelets (PLT) \u226580\u00d710\\^9/L\uff0cinternational standardized ratio (INR) \\<1.5;\n8. Hepatic function\uff1aalanine aminotransferase(ALT) and aspartate aminotransferase(AST) \u22642.5\u00d7ULN\uff0cserum total bilirubin\u22641.5\u00d7 ULN;\n9. Renal function\uff1ablood urea nitrogen(BUN) and serum creatinine(Cr) \u22641.5\u00d7ULN, or endogenous creatinine clearance rate(Ccr) \u226560mL/min;\n10. Without other severe cardiac disease or respiratory disease;\n11. The volunteers voluntarily join the study, sign informed consent, and have good compliance and follow-up.\n\nExclusion Criteria:\n\n1. Inappropriate to receive chemotherapy;\n2. Women who are pregnant, preparing to be pregnant, breastfeeding;\n3. Known or suspected hypersusceptibility to any agents used in the treatment protocol;\n4. With severe cardiac disease, respiratory disease, liver disease, kidney disease, or diabetes;\n5. With severe infection;\n6. With severe encapsulated pleural effusion or intrathoracic tissue adhesion which is inappropriate to receive thoracocentesis;\n7. With cognitive impairment or low compliance;\n8. Participating in other clinical trials within 4 weeks;\n9. Undergoing immunotherapy within 3 months;\n10. Other conditions considered to be inappropriate to be enrolled by the investigator.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}